- Patients
- Clinical Research
- Clinical trials
- PRIMORDIUM
2021-06-09T00:00:00.000+01:00
Ongoing
PRIMORDIUM
PRIMORDIUM
Prostate Cancer
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort. Study Details: The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane antigen-positron emission tomography (PSMA-PET) or death compared with RT plus LHRHa alone.
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort. Study Details: The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane antigen-positron emission tomography (PSMA-PET) or death compared with RT plus LHRHa alone.
Trial overview
Clinical Area
Radiation Oncology
Disease / Condition
Prostate cancer
Study Phase
III
Trial Identifiers
NCT04557059
https://clinicaltrials.gov/study/NCT04557059
GenesisCare Location(s)
Wembley (Oncology)
:::
Hurstville (Oncology)
:::
St Vincent’s Melbourne (Oncology)
:::